

**REMARKS**

Claims 60-70 are pending in the present application. Reconsideration and allowance of the claims is respectfully requested in view of the following remarks.

Claims 60-70 stand rejected under the judicially created doctrine of obviousness-type double patenting as allegedly being unpatentable over claims 5 and 7 of U.S. Patent No. 6,214,386. A terminal disclaimer signed by John, LaRocca, Vice President Law of the Purepac Pharmaceutical Company is submitted herewith.

It is believed that the foregoing amendments and remarks fully comply with the Office Action and that the claims herein should now be allowable to Applicants. Accordingly, reconsideration and allowance is requested.

If there are any additional charges with respect to this Amendment or otherwise, please charge them to Deposit Account No. 06-1130 maintained by Applicants' attorneys.

Respectfully submitted,

CANTOR COLBURN LLP

By Karen A. LeCuyer  
Karen A. LeCuyer, Ph.D.  
Reg. No. 51,928

Date: November 22, 2004

CANTOR COLBURN LLP  
55 Griffin Road South  
Bloomfield, CT 06002  
Telephone (860) 286-2929  
Facsimile (860) 286-0115  
Customer No. 23413